Best Weight Loss Drug Stocks
Last updated November 2026
Short answer
There is no single list of best weight-loss-drug stocks, because the right holdings depend on your goals and no one can predict prices. What dominates obesity portfolios is a spread across two roles. Two leaders with approved, blockbuster GLP-1 medicines own most of the market: LLY (Zepbound and Mounjaro) and NVO (Ozempic and Wegovy). Behind them sit the challengers and pipeline names still trying to catch up, which are earlier stage and far more dependent on clinical-trial results: VKTX, AMGN, and PFE. Keep the shape of this market in view: the two leaders dominate and trade at rich valuations, while the challengers are earlier-stage bets that can move hard on a single trial readout. The useful move is to treat a list like this as research and build a diversified portfolio from it, not to buy one name. Walnut, an AI investing app, can compare these names against your existing holdings. This page is descriptive and informational, not investment advice.
GLP-1 obesity drugs have been one of the biggest stories in healthcare, turning diabetes medicines into blockbuster weight-loss treatments and reshaping how investors think about big pharma. That backdrop produces endless headlines about the top weight-loss stocks to buy, which read like predictions, and predictions about individual stock prices are the one thing no one does reliably. So this guide takes a different approach. It groups the weight-loss-drug stocks people most widely hold and discuss in 2026 by their role in the market, separates the two entrenched leaders from the earlier-stage challengers, explains what each one actually does and the risks it carries, links each to a fuller page, and then shows how to turn a list like this into a portfolio instead of a single bet. Nothing here is a recommendation to buy or sell, and Walnut is not an investment adviser.
What is the GLP-1 obesity opportunity?
The reason weight-loss-drug stocks get so much attention is a real shift in medicine. GLP-1 drugs mimic a hormone that regulates appetite and blood sugar, and in trials they have produced substantial, sustained weight loss. That turned a class of diabetes treatments into blockbuster obesity medicines with a potential market far larger than the one they were first approved for. That is the mechanism behind the theme, and it is genuine.
But a large market is not a guarantee for any one stock.
- The leaders are richly valued. Eli Lilly and Novo Nordisk already trade on years of expected growth, so slowing sales, pricing pressure, or a strong competitor can trigger sharp drops even in a growing market.
- The challengers are trial-dependent. Viking, Amgen, and Pfizer are earlier stage. Their obesity value hinges on clinical results, and a single failed or disappointing readout can move them hard. A pure clinical-stage biotech has no approved product to cushion the fall.
- Competition and reimbursement are open questions. More entrants are targeting the same market, and how insurers price and cover these drugs will shape how much revenue actually reaches shareholders.
None of this is a recommendation. These points are the context you need to read the list below as research, with the healthcare headlines kept in proportion.
What weight-loss-drug stocks are most widely held in 2026?
Below are the GLP-1 and obesity names most widely held and discussed in 2026, grouped by the role each one plays in the market. For each, the note explains what the business does and why it is commonly held, not whether you should own it. Every name links to its own page with the deeper detail.
The two leaders (the GLP-1 duopoly)
The weight-loss-drug market is dominated by two companies with approved, blockbuster GLP-1 medicines already on the market and generating enormous revenue. Together they hold the overwhelming majority of prescriptions and manufacturing capacity, which is why almost every obesity-stock portfolio is anchored here. The standing caveat is that both trade at rich valuations that already price in years of continued growth, and any competitive or pricing setback can move them sharply.
- Eli Lilly (LLY). Eli Lilly makes tirzepatide, sold as Zepbound for weight loss and Mounjaro for diabetes, which has become one of the best-selling drug franchises in the industry. It is the most widely held obesity name and the one the theme is often benchmarked against, though it trades at one of the richest valuations among large pharma and prices in years of continued growth.
- Novo Nordisk (NVO). Novo Nordisk makes semaglutide, sold as Wegovy for weight loss and Ozempic for diabetes, the drugs that first turned GLP-1 into a household topic. It is commonly held as the co-leader of the duopoly, though it has faced questions about pipeline and competitive pressure that have made it more volatile than its scale would suggest.
The challengers and pipeline (earlier stage, trial-dependent)
Behind the two leaders sit companies trying to reach the same market with their own candidates, from a clinical-stage biotech to two large diversified drugmakers with obesity programs. These are held as ways to bet on the market broadening beyond a duopoly, but they are meaningfully earlier stage and far more dependent on clinical-trial results. A single failed or disappointing trial readout can move these names hard, and none has the entrenched, approved franchise the two leaders do.
- Viking Therapeutics (VKTX). Viking Therapeutics is a clinical-stage biotech developing its own obesity candidates, including an oral and an injectable GLP-1 program, that have drawn attention in mid-stage trials. It is held as the high-risk, high-reward pure-play challenger, but it has no approved product and its value hinges almost entirely on trial readouts, which makes it far more speculative and volatile than the leaders.
- Amgen (AMGN). Amgen is a large, established biotech with a differentiated obesity candidate (MariTide) in clinical development alongside a broad existing drug portfolio. It is held as a diversified way to get pipeline exposure, since obesity is one program among many, though its candidate is still trial-dependent and behind the leaders.
- Pfizer (PFE). Pfizer is a large diversified drugmaker that has been working on oral obesity candidates, with a program that has seen setbacks and restarts. It is held as a way to own a big-pharma attempt at the market at a lower valuation, but its obesity effort is earlier and less certain than the leaders, and progress has been uneven.
At a glance
The same names, grouped by role, so you can scan the breadth across the list. The order is not a ranking.
| Ticker | Company | What it does |
|---|---|---|
| LLY | Eli Lilly | Maker of Zepbound and Mounjaro (tirzepatide); the market leader by momentum. |
| NVO | Novo Nordisk | Maker of Ozempic and Wegovy (semaglutide); the co-leader of the market. |
| VKTX | Viking Therapeutics | Clinical-stage biotech with obesity candidates in trials; no approved product yet. |
| AMGN | Amgen | Established biotech with an obesity candidate in trials plus a broad existing portfolio. |
| PFE | Pfizer | Large diversified pharma pursuing oral obesity candidates; earlier and less certain. |
Is there a GLP-1 ETF, and does it get you beyond Lilly and Novo?
Two US-listed funds are built on the theme: the Roundhill GLP-1 & Weight Loss ETF (OZEM) and the Amplify Weight Loss Drug & Treatment ETF (THNR). Neither gets far from the two leaders. In mid-November 2026 OZEM held 22 companies with Eli Lilly at about 20% and Novo Nordisk at about 11%, so close to a third of the fund sat in those two. THNR held 23 companies with Lilly at about 12% and Novo at about 9%, and filled most of the rest with large drugmakers such as Amgen, Regeneron, AstraZeneca and Roche.
Where OZEM does go beyond the duopoly is Asia. Its top 10 included Hanmi Pharmaceutical, Chugai, CSPC, Jiangsu Hengrui and Hansoh, drugmakers with their own obesity candidates that US investors rarely see, plus Viking Therapeutics at about 4%. Both funds are small, about $58 million (OZEM) and $5 million (THNR) in assets, and small funds trade more thinly and are more likely to be closed by their issuer than large ones. Holdings are from each fund's published list as reported by StockAnalysis in November 2026; check the issuer's site for current weights and fees.
How do you build a portfolio from these instead of buying one?
A list of stocks is only the input to a portfolio. What turns it into one is structure: which roles you want exposure to, how much weight each name gets, and the discipline to keep no single position from dominating. That matters even more here, where the two leaders behave very differently from the trial-dependent challengers. A repeatable way to do it:
- Pick a thesis. Decide what view you are expressing. Owning the two leaders for their approved, cash-generating franchises is a very different portfolio from leaning on the challengers for pipeline upside.
- Separate leaders from pipeline. Holding Lilly and Novo is a bet on the entrenched duopoly. Adding a challenger like Viking is a bet on the market broadening, at much higher risk. Being deliberate about that split keeps a single trial readout from dominating your outcome.
- Set target weights. Assign each name a percentage that sums to 100, so concentration is something you chose. Otherwise it comes from whichever stock ran up. Sizing a speculative clinical-stage name smaller than an approved leader is a common way to reflect the risk difference.
- Compare against the S&P 500. Check how the mix would have tracked the benchmark, because a sector tilt should earn its keep versus just holding a broad index.
- Place the trades and review. Buy to your targets, then revisit periodically as weights drift or as trial results and competitive dynamics shift.
Walnut is built for this step. You create a thematic portfolio from the stocks you choose, set a target weight for each, see how the portfolio would track against the S&P 500, and place trades you approve yourself at your own broker. Walnut frames each holding against the S&P 500 and shows how the mix is concentrated, so the portfolio is a deliberate structure. Walnut does not tell you which stocks to buy.
If you would rather explore the theme as a ready-made portfolio or read about the wider sector, browse the GLP-1 and obesity drugs theme or see our guide to the best biotech stocks.
How we chose what to feature
On method: this is not a prediction and not a ranking. We did not forecast which weight-loss-drug stocks will rise, score them, or order them by expected return, because no one can do that reliably. We featured names on three descriptive criteria instead.
- Central to the theme. Each is a company the GLP-1 and obesity conversation actually centers on, from the two market leaders to the most-discussed challengers, so the page reflects what people follow.
- Role-representative. Each name illustrates a role in the market (the approved leaders versus the earlier-stage challengers and pipeline) so the list shows how an obesity portfolio is built, and how the risk differs, not which single stock to chase.
- Clear about stage. We flagged clearly which names have approved, revenue-generating drugs and which are earlier and trial-dependent, so the descriptions lean on where each company actually stands.
The result is a map of what tends to anchor weight-loss-drug portfolios in 2026 and how to think about it, not a buy list. Treat every name as a starting point for your own research. Trial results, approvals, competition, and valuations change; verify current details before you act.
The bottom line on the best weight loss drug stocks
There is no single answer to “what are the best weight loss drug stocks”, because the right holdings depend on your goals and no one can predict prices. What tends to anchor obesity portfolios is a spread across two roles: the two leaders that dominate the market with approved, blockbuster GLP-1 drugs, Eli Lilly and Novo Nordisk; and the challengers and pipeline names still trying to catch up, Viking Therapeutics, Amgen, and Pfizer, which are earlier stage and far more dependent on clinical-trial results. The leaders trade at rich valuations that price in years of growth, while the challengers can move hard on a single readout. The useful move is to treat a list like this as research and build a diversified, weighted portfolio from it across several names. Walnut helps you turn that into a thematic portfolio you control. It is not an investment adviser, and nothing here is a recommendation.
Your questions about weight loss drug stocks
Ask Walnut's AI anything about weight loss drug stocks and see how they fit what you own.
FAQ
What are GLP-1 stocks besides Novo Nordisk and Eli Lilly?
Commonly discussed names include Viking Therapeutics (a clinical-stage biotech), Amgen and Pfizer (large drugmakers with obesity programs), and a group of Asian drugmakers with their own candidates: Hanmi, Chugai, CSPC, Jiangsu Hengrui and Hansoh, all in the top 10 of the OZEM GLP-1 ETF in November 2026. Most are earlier stage than the leaders. This is a description, not a recommendation.
Is there a GLP-1 ETF?
Yes, two small ones: the Roundhill GLP-1 & Weight Loss ETF (OZEM, about $58 million in assets) and the Amplify Weight Loss Drug & Treatment ETF (THNR, about $5 million) as of November 2026. Both still lean on the leaders: Lilly and Novo were about 31% of OZEM and 21% of THNR. Check each issuer's site for current holdings and fees.
What are the best weight loss drug stocks to buy in 2026?
There is no single list of best weight-loss-drug stocks, because the right holdings depend on your goals, time horizon, and risk tolerance, and no one can predict prices. What this page shows instead is the GLP-1 and obesity names most widely held and discussed in 2026, grouped by role: the two leaders that dominate the market (LLY, NVO), and the challengers and pipeline names still competing to catch up (VKTX, AMGN, PFE). Treat them as a research starting point, not recommendations. Walnut is not an investment adviser.
What are GLP-1 drugs and why do they matter for these stocks?
GLP-1 drugs mimic a hormone that regulates appetite and blood sugar, and in trials they have produced substantial weight loss, which turned diabetes medicines into blockbuster obesity treatments. That expanded market is the reason these stocks get so much attention. The debate, and the risk, is how large the market ultimately becomes, how it is priced by insurers, and how many competitors share it, because a lot of future growth is already reflected in the leaders' valuations.
Which companies dominate the weight-loss-drug market?
Two companies dominate. Eli Lilly (LLY) makes tirzepatide, sold as Zepbound and Mounjaro, and Novo Nordisk (NVO) makes semaglutide, sold as Wegovy and Ozempic. Between them they hold the overwhelming majority of approved GLP-1 prescriptions and manufacturing capacity. The challengers, including Viking Therapeutics, Amgen, and Pfizer, are earlier stage and trial-dependent, so this is very much a market led by two entrenched players with others trying to catch up.
Are the challenger and pipeline stocks riskier than the leaders?
Generally yes, in different ways. The challengers like Viking Therapeutics are earlier stage and depend heavily on clinical-trial results, so a single disappointing readout can move them sharply, and a pure clinical-stage biotech has no approved product to fall back on. Amgen and Pfizer are larger and more diversified, so obesity is one program among many, but their candidates are still behind the leaders and trial-dependent. The leaders carry a different risk: high valuations that price in years of growth. None of this is a recommendation. Walnut is not an investment adviser.
Should I buy individual weight-loss-drug stocks or a biotech or healthcare ETF?
Both are common, and the choice is yours. An ETF spreads a single investment across many drugmakers and biotechs, so any one trial failure or competitive shift matters less. Individual stocks let you tilt toward a specific name or the leaders versus the challengers, at the cost of more concentration and more work, especially given how much a clinical-stage biotech can swing on trial news. Many investors use a broad healthcare or biotech fund as a base and add a few individual names. See our guide to the best biotech stocks for more on the broader sector.
What are the risks of weight-loss-drug stocks?
For the leaders, the biggest risk is valuation: a lot of expected growth is already in the prices, so slowing sales, pricing pressure from insurers, or a strong competitor can trigger sharp drops. For the challengers, the biggest risk is clinical: candidates can fail or disappoint in trials, and a clinical-stage biotech with no approved product can fall hard on a single readout. Across the theme there is competitive risk as more entrants target the same market, and regulatory and reimbursement risk. Spreading across leaders and pipeline helps but does not remove these risks.
Does Walnut recommend which weight-loss-drug stocks to buy?
No. Walnut is not a registered investment adviser and does not tell you what to buy. It lets you build a focused portfolio from weight-loss-drug stocks you choose, set target weights, see how the portfolio would track against the S&P 500, and place trades you approve yourself at your own broker. Every page here is descriptive and informational, not a recommendation.
From here you can dig into any individual stock, explore the GLP-1 and obesity drugs theme as a ready-made portfolio, or read our guide to the best biotech stocks for the wider sector.
Walnut is informational and is not a registered investment adviser. This page describes weight-loss-drug and GLP-1 stocks that are widely held and commonly discussed, grouped by role; it is not a prediction, a ranking, or a recommendation to buy, sell, or hold any security. Investing involves risk, including the possible loss of principal, and past performance does not indicate future results. Clinical-stage and pipeline names are especially speculative and can move sharply on trial results. Company facts, trial outcomes, and valuations change; verify current details before making any decision. Do your own research or consult a licensed financial professional.
ETFs and stocks in this guide
Invest in this theme
These names are grouped as a theme you can hold as one position and track against the S&P 500. See the glp-1 and obesity drugs theme, which shows the constituents, the ETF proxies, and how the group has performed together.